Efavirenz-loaded intranasal microemulsion for crossing blood-CNS interfaces in neuronal-AIDS: pharmacokinetic and in vivo safety evaluation

References

• Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. 2015. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 12(2):181–194.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Panciani PP, Muntoni E, Capucchio MT, Biasibetti E, De Bonis P, Mioletti S, Fontanella M, Swaminathan S. 2018. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv. 15:369–378.
   PubMed Web of Science ®Google Scholar
• Belgamwar A, Khan S, Yeole P. 2017. Intranasal chitosan-g-HP β CD nanoparticles of efavirenz for the CNS targeting. Artif Cells Nanomedicine Biotechnol. 46:374–386.
   PubMed Web of Science ®Google Scholar
• Bertrand L, Dygert L, Toborek M. 2016. Antiretroviral treatment with efavirenz disrupts the blood-brain barrier integrity and increases stroke severity. Sci Rep. 6:39738.
   PubMed Web of Science ®Google Scholar
• Bhavna , Md S, Ali M, Ali R, Bhatnagar A, Baboota S, Ali J. 2014. Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo Safety evaluation. Int J Biol Macromol. 67:418–425.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Gorain B, Tekade RK, Pandey M, Karmakar S, Pal TK. 2017. Safety against nephrotoxicity in paclitaxel treatment: oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. Regul Toxicol Pharmacol. 91:179–189.
   PubMed Web of Science ®Google Scholar
• Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, et al. 2010. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 54(10):4451–4463.
   PubMed Web of Science ®Google Scholar
• Gadhave D, Choudhury H, Kokare C. 2019. Neutropenia and leukopenia protective intranasal olanzapine-loaded lipid-based nanocarriers engineered for brain delivery. Appl Nanosci. 9(2):151–168.
   Web of Science ®Google Scholar
• Gadhave D, Gorain B, Tagalpallewar A, Kokare C. 2019. Intranasal teriflunomide microemulsion: an improved chemotherapeutic approach in glioblastoma. J Drug Deliv Sci Tech. 51:276–289.
   Web of Science ®Google Scholar
• Gadhave DG, Kokare CR. 2019. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev Ind Pharm. 45(5):839–851.
   PubMed Web of Science ®Google Scholar
• Gadhave DG, Tagalpallewar AA, Kokare CR. 2019. Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for CNS delivery: optimization and hematological toxicity studies. AAPS PharmSciTech. 20(1):22.
   PubMed Web of Science ®Google Scholar
• Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. 2010. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 388(1-2):231–241.
   PubMed Web of Science ®Google Scholar
• Giuliani A, Balducci AG, Zironi E, Colombo G, Bortolotti F, Lorenzini L, Galligioni V, Pagliuca G, Scagliarini A, Calzà L, Sonvico F. 2018. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv. 25(1):376–387.
   PubMed Web of Science ®Google Scholar
• Gomes MJ, Neves J, Sarmento B. 2014. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed. 9:1757–1769.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kesarla R, Chotai N, Misra A, Omri A. 2017. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res Int. 2017:5984014.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH. 2007. Strategies for intranasal delivery of therapeutics for the prevention and treatment of NeuroAIDS. J Neuroimmune Pharm. 2(1):81–86.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kawaguchi T. 2002. Delivery of anti-viral nucleoside analogues to the central nervous system. Curr Med Chem Anti Infect Agents. 1:55–63.
   Google Scholar
• Khan A, Imam SS, Aqil M, Ahad A, Sultana Y, Ali A, Khan K. 2016. Brain Targeting of Temozolomide via the Intranasal Route Using lipid based nanoparticle: Brain Pharmacokinetic and Scintigraphic. Mol Pharm. 13:3773–3782.
   PubMed Web of Science ®Google Scholar
• Kozlovskaya L, Abou-Kaoud M, Stepensky D. 2014. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 189:133–140.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. 2008. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target. 16(10):806–814.
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 45(1):89–121.
   PubMed Web of Science ®Google Scholar
• Lembo D, Cavalli R, Cliniche S, Torino O. 2010. Review nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 21(2):53–70.
   PubMedGoogle Scholar
• Mandlik SK, Ranpise NS, Mohanty BS, Chaudhari PR. 2018. A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers. Drug Deliv and Transl Res. 8(3):797–805.
   PubMed Web of Science ®Google Scholar
• Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, Ali J. 2013. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 48(3):393–405.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. 2009. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 379(1):146–157.
   PubMed Web of Science ®Google Scholar
• Patel RB, Patel MR, Bhatt KK, Patel BG. 2013. Formulation and evaluation of microemulsions-based drug delivery system for intranasal administration of olanzapine. Int J Biomed Pharm Sci. 7(1):20–27.
   Google Scholar
• Pathak R, Prasad Dash R, Misra M, Nivsarkar M. 2014. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route. Acta Pharm Sin B. 4(2):151–160.
   PubMed Web of Science ®Google Scholar
• Peroni RN, Di Gennaro SS, Hocht C, Chiappetta DA, Rubio MC, Sosnik A, Bramuglia GF. 2011. Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem Pharmacol. 82(9):1227–1233.
   PubMed Web of Science ®Google Scholar
• Pokharkar V, Patil-Gadhe A, Palla P. 2017. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study. Biomed Pharmacother. 94:150–164.
   PubMed Web of Science ®Google Scholar
• Pund S, Rasve G, Borade G. 2013. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur J Pharm Sci. 48(1-2):195–201.
   PubMed Web of Science ®Google Scholar
• Rao KS, Ghorpade A, Labhasetwar V. 2009. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv. 6(8):771–784.
   PubMed Web of Science ®Google Scholar
• Shah BM, Misra M, Shishoo CJ, Padh H. 2014. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 7544:1–13.
   Google Scholar
• Shinde RL, Bharkad GP, Devarajan PV. 2015. Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: role of docosahexaenoic acid. Eur J Pharm Biopharm. 96:363–379.
   PubMed Web of Science ®Google Scholar
• Shinde RL, Devarajan PV. 2017. Docosahexaenoic acid–mediated, targeted and sustained brain delivery of curcumin microemulsion. Drug Deliv. 24(1):152–161.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. 2006. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech. 7(1):E49–E57.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shah L, Amiji MM. 2006. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv. 3(5):613–628.
   PubMedGoogle Scholar
• Wang X, Chi N, Tang X. 2008. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm. 70(3):735–740.
   PubMed Web of Science ®Google Scholar